Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04460027 · ClinicalTrials.gov registry record · Phase 1
W-SUDs for COVID-19
A Phase 1 study, sponsored by Woebot Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
NCT04460027: Completed Phase 1 study, sponsored by Woebot Health.
NCT04460027 is a Phase 1 study that has completed, run by Woebot Health. The registered enrollment target is 180 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (200% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04460027, a Phase 1 study, has completed, sponsored by Woebot Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic. This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to a wait list control condition, and explore between group differences on quality of life indices as well as retention and engagement during COVID-19.
Primary Outcome
Change in number of substance use occasions in the past 30 days from Baseline to Post-treatment at 8 weeks
Interventions
- OTHER Woebot Substance Use Disorder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2020-11-30 |
| Phase | Phase 1 |
What the finished NCT04460027 record still lists
NCT04460027 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (200% higher).
The record links to 0 conditions, and to 1 intervention - of which Woebot Substance Use Disorder is the first listed.
NCT04460027 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04460027 about?
NCT04460027 is a clinical study titled "W-SUDs for COVID-19". The purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic. This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce subs...
What is the current status of trial NCT04460027?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2020-06-22. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT04460027?
The interventions under investigation include: Woebot Substance Use Disorder (OTHER).
Who is sponsoring clinical trial NCT04460027?
This trial is sponsored by Woebot Health, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04460027's enrollment target sits among peer trials
180 299th of 2000 higher than 1,690 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI